US speciality pharmaceutical company Actavis Inc (NYSE:ACT) said it had engaged in early-stage talks to potentially combine with Irish sector player Warner Chilcott plc (NASDAQ:WCRX).
The US firm noted that the parties had not agreed on a deal yet and it would not comment further on its business development initiatives.
Warner Chilcott, which put itself on the block over a year ago, confirmed in a separate statement that preliminary negotiations were being held which are not certain to result in an offer for the company.
Actavis was previously discussing a tie-up with Canadian peer Valeant Pharmaceuticals International Inc (TSE:VRX) but the talks were put on ice as the parties could reach an accord on the terms of the potential merger.
Warner Chilcott has a market value of some $3.8bn (€2.9bn).